newsfilter
← Earnings
Earnings Releases·

Exagen Inc. — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue reached $18.4 million (up 7% YoY) and net loss narrowed to $6.3 million (down 12% YoY), while full-year revenue guidance remains unchanged at $72 million to $75 million.
  • The company acquired an AI-enabled rheumatology workflow platform in July 2026, recognized a $587,000 IPR&D charge, and reported a 14th consecutive quarter of ASP growth for AVISE CTD to $451 per test.
  • Future outlook includes a planned launch of the myositis offering in early 2027 and a dedicated webcast on pipeline development scheduled for December 15, 2026.
  • Cash and cash equivalents declined to $28.1 million as of September 30, 2026, from $35.7 million the prior year, while total liabilities rose slightly to $41.6 million.
Company
EXAGEN INC
Sector
Healthcare
Industry
Diagnostics & Research